Viracta Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Mark Rothera
Chief executive officer
US$1.5m
Total compensation
CEO salary percentage | 40.5% |
CEO tenure | 2yrs |
CEO ownership | n/a |
Management average tenure | 3.2yrs |
Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$45m |
Mar 31 2024 | n/a | n/a | -US$48m |
Dec 31 2023 | US$1m | US$590k | -US$51m |
Sep 30 2023 | n/a | n/a | -US$48m |
Jun 30 2023 | n/a | n/a | -US$53m |
Mar 31 2023 | n/a | n/a | -US$51m |
Dec 31 2022 | US$6m | US$167k | -US$49m |
Compensation vs Market: Mark's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD508.57K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Rothera (61 yo)
2yrs
Tenure
US$1,456,596
Compensation
Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 2yrs | US$1.46m | no data | |
Chief Medical Officer | 1.1yrs | US$1.05m | 0% $ 0 | |
Scientific Founder and Consultant | 13.8yrs | no data | no data | |
Co-Founder and Consultant | 13.8yrs | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Scientific Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Scientific Officer | 3.2yrs | no data | no data | |
Senior Vice President of Regulatory Affairs | 3.5yrs | no data | no data | |
Senior Vice President of Business Development & Corporate Strategy | 3.2yrs | no data | no data |
3.2yrs
Average Tenure
61yo
Average Age
Experienced Management: RYI's management team is considered experienced (3.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 2yrs | US$1.46m | no data | |
Scientific Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
Director | 3.6yrs | US$90.76k | 2.11% $ 168.5k | |
Independent Director | 3.6yrs | US$113.26k | 0% $ 0 | |
Member of Scientific Advisory Board | 6yrs | no data | no data | |
Member of Scientific Advisory Board | 6yrs | no data | no data | |
Independent Director | 3.5yrs | US$110.76k | 0% $ 0 | |
Independent Chairman of the Board | 3.6yrs | US$210.27k | 0.30% $ 23.7k | |
Member of Scientific Advisory Board | 6yrs | no data | no data | |
Member of Scientific Advisory Board | 6yrs | no data | no data | |
Member of Scientific Advisory Board | 6yrs | no data | no data | |
Independent Director | 3.5yrs | US$108.26k | 0% $ 0 |
3.6yrs
Average Tenure
67yo
Average Age
Experienced Board: RYI's board of directors are considered experienced (3.6 years average tenure).